I
Ian Quirt
Researcher at University of Toronto
Publications - 52
Citations - 15342
Ian Quirt is an academic researcher from University of Toronto. The author has contributed to research in topics: Cancer & Chemotherapy. The author has an hindex of 23, co-authored 52 publications receiving 13834 citations. Previous affiliations of Ian Quirt include Ontario Institute for Cancer Research & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
Kim Margolin,Jeffrey Longmate,Tracey Baratta,Tim Synold,Scott D Christensen,Jeffrey S. Weber,Thomas F. Gajewski,Ian Quirt,James H. Doroshow +8 more
TL;DR: CCI‐779 is an analog of the immunosuppressive agent, rapamycin, that has demonstrated activity against melanoma in preclinical models and shown clinical benefit in patients with breast and renal carcinoma.
Journal ArticleDOI
Outcome and prognostic factors in soft tissue sarcoma in the adult
J. Levay,Brian O'Sullivan,Charles Catton,Robert S. Bell,Victor Fornasier,Bernard Cummings,D. Hao,D Warr,Ian Quirt +8 more
TL;DR: This series highlights the overall problem of distant failure in soft tissue sarcoma and reaffirms the importance of obtaining local control both in the head and neck, where uncontrolled local disease is the major cause of death, and in general since local relapse appears to increase the risk of distantFailure.
Journal ArticleDOI
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Joseph M. Connors,Paul Klimo,Grenfell Adams,Bruce F. Burns,Ian Cooper,Ralph M. Meyer,Susan E. O'Reilly,J. Pater,Ian Quirt,Anna Sadura,Chaim Shustik,J. Skillings,Simon Sutcliffe,Shailendra Verma,Sam Yoshida,Benny Zee +15 more
TL;DR: MOPp/ABV hybrid and alternating MOPP/ABVD regimens are equally effective for patients with advanced Hodgkin's disease.
Journal ArticleDOI
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
TL;DR: No systemic adjuvant therapy was identified that conferred a significant overall survival benefit in patients with high‐risk, resected, primary melanoma, but high‐dose interferon should be considered in the treatment of these patients, because such therapy is associated with a significant improvement in disease‐free survival and a reduction in 2‐year mortality.